Tina Colombo

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

Tinya J. Abrams, Lesley Murray, Enrico Pesenti et al. · PubMed · 2003 · 252 citations

Breast Oncology, Drug Targeting, Single Agent +15

Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model

Daniel L. Gustafson, Jeffrey C. Rastatter, Tina Colombo et al. · Journal of Pharmaceutical Sciences · 2002 · 103 citations

Doxorubicin Pharmacokinetics, Health Sciences, Physiologically-based Pharmacokinetic Modeling +8

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

Maurizio D’Incalci, Tina Colombo, Paolo Ubezio et al. · European Journal of Cancer · 2003 · 90 citations

Oncology, Human Tumor Xenografts, Medicine +7

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

Riccardo Riccardi, Daniela Meco, Tina Colombo et al. · Cancer Chemotherapy and Pharmacology · 2003 · 76 citations

Malignant Disease, Effective Combination, Medicine +6

IDN5109, a taxane with oral bioavailability and potent antitumor activity.

Maria Nicoletti, Tina Colombo, Cosmo Rossi et al. · PubMed · 2000 · 74 citations

Tumor Biology, New Taxane, Oral Bioavailability +14